International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 04 Issue 11 November 2024

Page No: 2067-2069

DOI: https://doi.org/10.47191/ijmscrs/v4-i11-20, Impact Factor: 7.949

The Most Recent Information Regarding the Management of Stevens - Johnson syndrome And Toxic Epidermal Necrolysis.

Daniela Lizbeth Casillas Sandoval[1], Susana Jiménez Flores[2]

[1,2]Universidad Michoacana de San Nicolás de Hidalgo.

ABSTRACT

The dermatological conditions known as Stevens - Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening conditions that are characterized by extensive epidermal necrolysis and sloughing. The incidence rates differ from one location to another, with the United Kingdom experiencing an annual incidence of 5.76 cases per million people between the years 1995 and 2013. In terms of mortality rates, females are more likely to be affected than males, with mortality rates ranging from 4.8-9% to 14.8-48%.

Providing patients with SJS or TEN with nonpharmacologic treatment consists of providing supportive care, managing fluid and electrolyte levels, controlling infections, and treating wounds. The identification and the elimination of the substance that is responsible for the condition is the most important component. Patients with SJS or TEN have lower fluid requirements than burn patients, so it is essential that they receive proper management of their fluid, electrolyte, and nutritional needs.

Antibiotics used as a preventative measure do not improve outcomes; however, infection prevention requires proper wound care and the use of antiseptic handling. The decision to pursue surgical debridement as a treatment option is contingent on the location of care where the patient is being treated. The role of surgical debridement has been the subject of debate. It has been demonstrated that anti-shear therapy, which entails the aspiration of blister fluid and the preservation of denuded epidermis, is effective in lowering mortality rates.

Because SJS/TEN is such a rare disease, there have been very few prospective studies conducted on the subject of pharmacologic treatment for the condition. There have been a number of different treatment regimens that have been reported, including corticosteroids, IVIg, cyclosporine, and TNF-alpha inhibitors; however, it is difficult to determine whether the remission of the disease was due to a particular treatment or whether it was the natural course of the disease.

KEYWORDS: Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis, and cutaneous adverse drug reactions.

ARTICLE DETAILS

Published On:
16 November 2024

Available on:
https://ijmscr.org/

INTRODUCTION

Dermatological emergencies, such as Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are characterized by extensive epidermal necrolysis and sloughing [1, 2]. Both of these conditions are used interchangeably. Both of these conditions are classified according to the body surface area (BSA) that is affected, and it is presumed that they share the same pathophysiology. When it comes to these uncommon diseases, the incidence rates that have been reported can vary significantly depending on the location. The mortality rates for SJS, SJS/TEN, and TEN are between 4.8 and 9 percent, 19.4 and 29 percent, and 14.8 and 48 percent, respectively [3].

Treatment without the use of pharmaceuticals

Patients diagnosed with SJS/TEN are typically given supportive care as their primary treatment. This care includes the management of fluid and electrolyte levels, the prevention of infection, wound care, and the cessation of the substance that caused the condition. The identification and elimination of the substance that is responsible for the condition is the most important of these components. On the other hand, in

order to achieve the most favorable results, it is absolutely necessary to optimize each measure [4].

As a result of insensible losses through wounds, the management of fluid, electrolytes, and nutrition is of the utmost importance for patients suffering from SJS/TEN.

This is because the requirements of burn patients are precisely the same. On the other hand, the fluid requirements of patients with SJS and TEN are approximately thirty percent lower than those of burn patients with comparable degrees of cutaneous involvement. It is recommended that the environment be kept at a temperature between 30 and 32

Degrees Celsius because the skin loses its ability to regulate its own temperature. Urine output should aim to be between 0.5 and 1 milliliter per kilogram per hour in order to facilitate fluid replacement. At the earliest possible opportunity, enteral nutrition should be administered, and if necessary, nasogastric tube feedings should be administered as well [5, 6].

However, infection prevention requires appropriate wound care and antiseptic handling. Prophylactic antibiotics do not improve outcomes; however, they do promote infection prevention. The role of surgical debridement has been the subject of debate, and the decision to pursue this treatment option is contingent on the location of the care that is being provided. It is possible that anti-shear therapy, which is an alternative to surgical debridement, could reduce the amount of pain experienced as well as the amount of money spent in the hospital. In spite of this, there is a lack of high-quality evidence that can effectively guide decision-making regarding surgical debridement. Therefore, additional research is required in order to acquire a comprehensive understanding of the role that the therapy plays [7].

A limited number of prospective studies have been conducted to investigate the effectiveness of specific adjunctive therapies for SJS/TEN. This is because the disease is relatively uncommon. The result of this is that there is no predetermined standard of care for the administration of pharmacologic treatment. As a result of the immunologic nature of the disease, it is believed that immunosuppressive therapies will be helpful in the treatment process. Numerous case reports have reported positive results with a variety of treatment regimens that involve different combinations of corticosteroids, IVIg, cyclosporine, and TNF-alpha inhibitors. Nevertheless, it is difficult to determine whether the remission of the disease was the result of a particular treatment or whether it was the natural course of the disease. For the purpose of elucidating the role that pharmacologic therapies play in the treatment of SJS/TEN, numerous systematic reviews and meta-analyses have been conducted in an effort to address the methodologic limitations that have been identified. There is ongoing discussion regarding the extent to which corticosteroids can be used as monotherapy. The function of IVIg has also been the subject of debate, and it would appear that monotherapy does not appear to be associated with any mortality benefit being associated with it [8].

Because of their immunosuppressive properties, TNF-alpha inhibitors are also of relevance in this context [9].

Modifications to the SJS/TEN Management Category

Early recognition is a diagnostic criterion that can be improved with the help of tools such as the SCORTEN score, which will help predict severity and mortality.I am a When it comes to diagnosis, histopathological confirmation is absolutely necessary for a biopsy [10].

Initial Management: Immediately putting an end to the agents that are causing the harm: The identification and discontinuation of harmful medications (such as antibiotics and anticonvulsants) at an early stage is of the utmost importance.I am a Patients who have extensive skin involvement should be managed in specialized units, and referrals should be made to the burn unit or the intensive care unit [11].

The management of fluids and electrolytes is an essential component of supportive care, as it helps to prevent dehydration and renal failure. In order to preserve the integrity of the gut, enteral feeding is the preferred method of nutritional support.I am a Care for wounds should include the application of non-adherent dressings and topical antimicrobials in order to avoid secondary infections when possible. Controlling the temperature: In order to avoid hypothermia, it is important to keep the environment warm [12].

Treatments Involving PharmacologyIn the early stages of the disease, systemic corticosteroids may be beneficial for some patients, despite the fact that they are controversial.I am a Although there is conflicting evidence, some studies suggest that intravenous immunoglobulin (IVIG) may be beneficial in halting the progression of disease.I am a It is becoming increasingly clear that cyclosporine is an effective treatment for lowering mortality rates and facilitating a more rapid recovery. The agents known as TNF-α inhibitors, such as etanercept, are currently being investigated for their potential advantages in the management of SJS/TEN [13].

New Therapeutic Approaches [14]

Research into the potential of mesenchymal stem cell therapy to promote healing and reduce inflammation is currently being conducted under the supervision of researchers. In the case of ocular involvement, amniotic membrane grafts are utilized to prevent scarring and the loss of vision respectively.

- Biologics: The immunomodulatory effects of more recent biologic agents are currently the subject of research.

Ongoing Observation and Follow-UpIt is essential to conduct long-term follow-up in order to detect late complications such as ocular sequelae, scarring, and psychological impact. - Routine ophthalmologic examinations: for the purpose of monitoring and managing eye involvement, as well as preventing blindness.

• Individualized Care: Both the patient's specific needs and the severity of their condition should be taken into consideration when developing a treatment plan.

In order to provide comprehensive care, it is essential to involve a multidisciplinary approach, which includes the participation of specialists such as intensivists, ophthalmologists, and dermatologists.

• Research and Guidelines: In order to maximize the effectiveness of management strategies, it is necessary to conduct ongoing research and to regularly update clinical guidelines.

CONCLUSIONS

When determining the most effective pharmacological treatment for SJS/TEN, it is necessary to take into account practical considerations, such as cost, because there is a lack of consensus regarding the treatment that is the most effective.

REFERENCES

I. Frantz, R., Huang, S., Are, A., & Motaparthi, K. (2021). Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. Medicina, 57(9), 895.

II. Obeid, G., Valeyrie-Allanore, L., & Wolkenstein, P. (2015). Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS).

III. Chiu, Y. M., & Chiu, H. Y. (2023). Lifetime risk, life expectancy, loss-of-life expectancy and lifetime healthcare expenditure for Stevens–Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019. British Journal of Dermatology, 189(5), 553-560.

IV. Jacobsen, A., Olabi, B., Langley, A., Beecker, J., Mutter, E., Shelley, A., ... & Pardo, J. P. (2022). Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database of Systematic Reviews, (3).

V. Shah, H., Parisi, R., Mukherjee, E., Phillips, E. J., & Dodiuk-Gad, R. P. (2024). Update on Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management. American Journal of Clinical Dermatology, 1-18.

VI. Creamer, D., Walsh, S. A., Dziewulski, P., Exton, L. S., Lee, H. Y., Dart, J. K. G., ... & Brain, A. G. (2016). UK guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016. British Journal of Dermatology, 174(6), 1194-1227.

VII. Fernando, S. L. (2012). The management of toxic epidermal necrolysis. Australasian journal of dermatology, 53(3), 165-171.

VIII. Chang, H. C., Wang, T. J., Lin, M. H., & Chen, T. J. (2022). A review of the systemic treatment of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis. Biomedicines, 10(9), 2105.

IX. Zidi, I., Mestiri, S., Bartegi, A., & Amor, N. B. (2010). TNF-α and its inhibitors in cancer. Medical Oncology, 27, 185-198.

X. Koh, H. K., Fook-Chong, S. M., & Lee, H. Y. (2022). Improvement of mortality prognostication in patients with epidermal necrolysis: the role of novel inflammatory markers and proposed revision of SCORTEN (Re-SCORTEN). JAMA dermatology, 158(2), 160-166.

XI. Marks, M. E., Botta, R. K., Abe, R., Beachkofsky, T. M., Boothman, I., Carleton, B. C., ... & Phillips, E. J. (2023). Updates in SJS/TEN: collaboration, innovation, and community. Frontiers in Medicine, 10, 1213889.

XII. Thomas, D. R., Cote, T. R., Lawhorne, L., Levenson, S. A., Rubenstein, L. Z., Smith, D. A., ... & Council, D. (2008). Understanding clinical dehydration and its treatment. Journal of the American Medical Directors Association, 9(5), 292-301.

XIII. Cao, J., Zhang, X., Xing, X., & Fan, J. (2023). Biologic TNF-α inhibitors for Stevens–Johnson Syndrome, toxic epidermal necrolysis, and TEN-SJS overlap: a study-level and patient-level meta-analysis. Dermatology and Therapy, 13(6), 1305-1327.

XIV. Marks, M. E., Botta, R. K., Abe, R., Beachkofsky, T. M., Boothman, I., Carleton, B. C., ... & Phillips, E. J. (2023). Updates in SJS/TEN: collaboration, innovation, and community. Frontiers in Medicine, 10, 1213889.